Navigation Links
Enlivex Therapeutics Publishes Positive Results from Phase I/II Clinical Trial for the Treatment of Bone Marrow Transplant Recipients
Date:11/4/2013

JERUSALEM, Nov. 4, 2013 /PRNewswire/ -- Hadasit Bio-Holdings Ltd. (TASE: HDST, OTC: HADSY), a publicly traded portfolio of biotech companies, all based on intellectual property developed and owned by Hadassah University Hospital, Israel's foremost medical research center, today announced that its portfolio company Enlivex has published a scientific paper in the official publication of the American Society for Blood and Marrow Transplantation - 'Biology of Blood and Marrow Transplantation'. Hadasit Bio-Holdings holds a 92% stake in Enlivex.

The peer-reviewed paper provides additional validation to the Phase I/II results and emphasizes the significance of its findings.  The findings were based on a 13 patient trial conducted in three clinical centers in Israel.  The patients were given four escalating doses of ApoCell, Enlivex's lead product, shortly before a bone marrow transplant from a foreign donor. No safety concerns were observed in any of the doses and GvHD morbidity levels were significantly reduced. 

One of the main concerns in receiving bone marrow transplants from a donor is Graft-versus-Host Disease (GvHD). GvHD is an auto-immune type disease in which the immune system, including the new transplant, attacks organs of the patient, primarily the liver, intestines and skin. The disease can cause significant morbidity and is usually fatal if a patient reaches high grades. To date, no effective treatment has been found for this disease and up to 70% of transplant recipients suffer from this illness.

ApoCell is based on a cellular treatment developed in Hadassah Ein Kerem by Prof. Dror Mevorach, an expert in diseases of the immune system. The treatment is based on normal biological activity and initiates a state of 'immune tolerance' allowing the implant to fight the patients' cancer while significantly reduc
'/>"/>

SOURCE Hadasit Bio-Holdings Ltd.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Hadasit Bio-Holdings Flagship Portfolio Company Enlivex Awarded Orphan Drug Status for ApoCell Treatment by the FDA
2. Cell Therapeutics, Inc. (CTI) to Report First Quarter Financial Results on April 20
3. Faruqi & Faruqi, LLP Encourages Investors Who Suffered Substantial Losses Investing in Chelsea Therapeutics International, Ltd. to Contact the Firm
4. Argos Therapeutics Secures $25 million Series D Financing to Commence Phase 3 ADAPT Study in Patients with Metastatic Renal Cell Carcinoma (mRCC) in Mid-2012
5. Novelos Therapeutics Announces Successful Completion of First Cohort In Lung Cancer Trial With I-124-CLR1404 (LIGHT) Cancer-Targeted PET Imaging Agent at UW Carbone Cancer Center
6. Zacks Industry Outlook Highlights: Eli Lilly, Forest Labs, ViroPharma, Novartis and United Therapeutics
7. Oxford BioTherapeutics Appoints Senior Industry Leader to Head its New Clinical Development Operations in Basel, Switzerland
8. Nektar Therapeutics Reports Financial Results for the First Quarter of 2012
9. Cara Therapeutics Licenses Novel Kappa Opioid Agonist, CR845, to Chong Kun Dang Pharmaceutical Corporation For South Korean Market
10. Frost & Sullivan: High Uptake of New Drug Therapies and Aging Population Expansion Keep the U.S. Retinal Therapeutics Market Buoyant
11. Zenobia Therapeutics, Inc. And BioBlocks, Inc. Announce Sale Of A Joint Fragment Library Ideal For Screening By All Popular Methods
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/16/2014)... Sept. 16, 2014  Wearable sports and activity ... less than two years, producing a massive amount ... huge opportunity exists for leveraging this data to ... ) introduced a first-of-its-kind wearable analytics platform for ... of clinical research linking activity and health risks, ...
(Date:9/16/2014)... Sept. 16, 2014  Relmada Therapeutics, Inc., (OTCBB: RLMD), ... of chronic pain, announced today that it has entered ... (MSKCC) in a series of animal studies for levorphanol, ... extended release form of levorphanol.  Gavril Pasternak, MD, PhD, ... Dr. Pasternak said, "Levorphanol is a ...
(Date:9/16/2014)... 2014 Henry Schein, Inc. (NASDAQ: ... health care products and services to office-based dental, ... Stanley M. Bergman, Henry Schein,s Chairman of the Board and ... services panel at the Leerink Partners Services Roundtable on Tuesday, ... Dr. Stohler, Dean of Columbia University,s College of ...
Breaking Medicine Technology:Doctors Launch Initiative to Bridge Gap Between Wearables and Meaningful Health Data 2Doctors Launch Initiative to Bridge Gap Between Wearables and Meaningful Health Data 3Relmada Therapeutics Enters Into Agreement with Memorial Sloan Kettering to Better Clarify Unique Mechanism of Action for LevoCap ER 2Relmada Therapeutics Enters Into Agreement with Memorial Sloan Kettering to Better Clarify Unique Mechanism of Action for LevoCap ER 3Henry Schein To Present At The Leerink Partners Services Roundtable 2
(Date:9/16/2014)... York, NY (PRWEB) September 16, 2014 After ... program as one of the premier fertility centers in the ... Paul Gindoff have returned to their hometown of New York ... with Chelsea IVF and Genetics Labs. , Chelsea Fertility ... of becoming a parent in the New York Tri-State Area, ...
(Date:9/16/2014)... New York, NY (PRWEB) September 16, 2014 ... they are actually hungry, but for comfort during times ... consist of fatty, sugar laden treats that may provide ... as well as sabotaging the best laid weight loss ... Diet Plans that provide patients with the skills ...
(Date:9/16/2014)... YELM, Washington (PRWEB) September 16, 2014 ... to attend the Capstone Event in Yelm, Washington, Oct. ... event finishes the year and caps off the remarkable ... around the world in Switzerland, Italy, Australia, South Korea, ... is $1000, half price for children ages 6-19 and ...
(Date:9/16/2014)... 2014 With Pfister Energy Inc as ... Antonio, TX. has been awarded a solar technology contract ... US, including Alaska and Hawaii, U.S. Territories and the ... (EITF) and the Corps of Engineers, Engineering and Support ... to fund renewable and alternative energy projects greater than ...
(Date:9/16/2014)... 2014 Dr. Randy Carlson and ... the Love Your Marriage event is coming to ... helping married couples to better communicate, increase intimacy and have ... evening of fun, encouragement and learning to strengthen your marriage ... 26 – Living Word Bible Church (Mesa), Saturday, Sept. 27 ...
Breaking Medicine News(10 mins):Health News:Chelsea Fertility NYC Offers New and Affordable Fertility Treatment Options for Patients in the New York Tri-State Area 2Health News:Chelsea Fertility NYC Offers New and Affordable Fertility Treatment Options for Patients in the New York Tri-State Area 3Health News:Chelsea Fertility NYC Offers New and Affordable Fertility Treatment Options for Patients in the New York Tri-State Area 4Health News:Diet Doc Announces Emotional Eaters Diet Plans to Help Patients Break the Cycle for Fast and Permanent Weight Loss 2Health News:Diet Doc Announces Emotional Eaters Diet Plans to Help Patients Break the Cycle for Fast and Permanent Weight Loss 3Health News:Ramtha School Presents Capstone Event in Yelm Oct. 20-26 2Health News:Solar Construction Opportunity at U.S Army Installations Awarded to Pfister Energy & Infinity Development 2Health News:The Intentional Living Center Introduces the Love Your Marriage Night Featuring Dr. Randy Carlson in Arizona 2
... Sciton Inc., a manufacturer,of laser and ... announced the introduction of an additional fractional,device, ... features,-- significantly higher speed, and user-controlled, variable-depth ... results and excellent practice,economics., Up to ...
... Babies born,preterm were more than twice as likely ... a new analysis of nearly 7 million U.S.,live births ... and,Child Health Journal., Preterm birth, live birth before ... according to the March of Dimes. More than,a half ...
... that the frequency with which critically-ill patients developed,ventilator-associated ... medical center such as Mayo Clinic compared to ... National Healthcare Safety,Network (NHSN). This is good news ... generally strong across the U.S. in intensive care ...
... Dots beads led to a voluntary recall of the product ... that the potentially toxic chemical 1,4-butanediol (BD) had been used ... in the manufacture of the beads. , A new study, ... Irvine confirms these reports, finding that Aqua Dots contained no ...
... Inc. (OTC,Bulletin Board: SYMD) announced today that its Board ... The shareholder rights plan is,designed to ensure that shareholders ... an attempted takeover of the company and to protect ... plan,was not approved for adoption as a result of ...
... But, it may not be for every patient, one expert ... advanced prostate cancer that hasn,t spread beyond the gland should ... removed, a new long-term study says. , "What we are ... men who were treated with radiation and those who weren,t," ...
Cached Medicine News:Health News:Sciton Introduces ProFractional-XC(TM), High-Speed, Dual-Mode Fractional Laser 2Health News:Analysis of Millions of U.S. Births Shows Association Between Birth Defects and Preterm Birth 2Health News:Mayo Clinic Research Shows U.S. Intensive Care Units' Prevention of Pneumonia in Critically-ill Patients Generally Strong; Identifies Area of Improvement 2Health News:Mayo Clinic Research Shows U.S. Intensive Care Units' Prevention of Pneumonia in Critically-ill Patients Generally Strong; Identifies Area of Improvement 3Health News:Study finds that recalled Aqua Dots did contain poisonous chemical 2Health News:SyntheMed, Inc. Adopts Shareholder Rights Plan 2Health News:Radiation Improves Survival for Advanced Prostate Cancer 2Health News:Radiation Improves Survival for Advanced Prostate Cancer 3
... The Veris physiological monitor offers a comprehensive ... specifically designed for pediatric and neonate patients, ... to 3T. Veris is the first MR ... of pediatric and neonate patient monitoring. The ...
The SonoSite MicroMaxx gives you big machine performance in a lightweight package. This laptop-sized, durable unit represents the technology crossover point between hand-carried ultrasound and larger...
The IDS Gamma-B 25-Hydroxy Vitamin D kit is a conventional liquid phase radioimmunoassay intended for the quantitative determination of 25-hydroxy vitamin D (25-OHD) and other hydroxylated metabolite...
... is a fully automated ... for clotting, photometric and ... tests.The medium-throughput analyser offers ... tubes, 45 reagents onboard, ...
Medicine Products: